secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134793
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500
--------------------------------------------------------------------------------

- Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
- Over 17,500 prescriptions dispensed launch-to-date (+361% vs last quarterly report); >3,800 prescribers.
- SG&A expenses $62.0M (up from $18.6M YoY) reflecting commercial infrastructure build and marketing.
- Cigna added VOQUEZNA to formularies; commercial coverage now ~48% of U.S. commercial lives (~72M covered).
- FDA PDUFA date July 19, 2024 for NERD indication; Phase 3 NERD and Phase 2 EoE studies planned later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/0001193125-24-134793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312524134793/d837391d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer